Therapeutic targets for HIV-1 infection in the host proteome
暂无分享,去创建一个
Sampsa Hautaniemi | Tanya M. Teslovich | Winnie S. Liang | D. Stephan | F. Kashanchi | E. Agbottah | S. Hautaniemi | W. Liang | K. Kehn | C. de la Fuente | Anil Maddukuri | A. Pumfery | Tanya M Teslovich | Winnie S Liang | Dietrich A Stephan | Cynthia de la Fuente | Anil Maddukuri | Shabnam Dadgar | Anne Pumfery | Fatah Kashanchi | Emmanuel Agbottah | Kylene Kehn | S. Dadgar | Kylene W. Kehn | Cynthia de la Fuente
[1] F. Kashanchi,et al. Antiviral Activity of CYC202 in HIV-1-infected Cells* , 2005, Journal of Biological Chemistry.
[2] S. Zeichner,et al. Host Cell Gene Expression during Human Immunodeficiency Virus Type 1 Latency and Reactivation and Effects of Targeting Genes That Are Differentially Expressed in Viral Latency , 2004, Journal of Virology.
[3] K. Jeang,et al. Specific TATAA and bZIP requirements suggest that HTLV-I Tax has transcriptional activity subsequent to the assembly of an initiation complex , 2004, Retrovirology.
[4] F. Kashanchi,et al. The expanding role of Tax in transcription , 2004, Retrovirology.
[5] B. Berkhout,et al. Inhibiting HIV-1 entry with fusion inhibitors. , 2003, Current medicinal chemistry.
[6] M. Stevenson,et al. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection , 2003, Nature.
[7] Jaakko Astola,et al. Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps , 2003, Machine Learning.
[8] Hiroaki Sakurai,et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. , 2003, Molecular cancer therapeutics.
[9] F. Kashanchi,et al. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. , 2003, Current HIV research.
[10] F. Kashanchi,et al. Paradoxical effects of a stress signal on pro- and anti-apoptotic machinery in HTLV-1 tax expressing cells , 2003, Molecular and Cellular Biochemistry.
[11] M. Hart,et al. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. , 2003, The Journal of general virology.
[12] Jerome H. Kim,et al. HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. , 2003, Virology.
[13] Roger E Bumgarner,et al. Cellular Gene Expression upon Human Immunodeficiency Virus Type 1 Infection of CD4+-T-Cell Lines , 2003, Journal of Virology.
[14] A. Giordano,et al. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines , 2002, Oncogene.
[15] C. Ambrosino,et al. Physical and Functional Interaction of HIV-1 Tat with E2F-4, a Transcriptional Regulator of Mammalian Cell Cycle* , 2002, The Journal of Biological Chemistry.
[16] L. Meijer,et al. Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins , 2002, Journal of Virology.
[17] F. Kashanchi,et al. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals , 2002, BMC Biochemistry.
[18] T. Shirasawa,et al. Transgenic expression of the EXT2 gene in developing chondrocytes enhances the synthesis of heparan sulfate and bone formation in mice. , 2002, Biochemical and biophysical research communications.
[19] T. Maniatis,et al. An extensive network of coupling among gene expression machines , 2002, Nature.
[20] J. Dausset,et al. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule , 2002, AIDS.
[21] F. Kashanchi,et al. Enhancement of Nuclear Factor-κB Acetylation by Coactivator p300 and HIV-1 Tat Proteins* , 2002, The Journal of Biological Chemistry.
[22] M. Tremblay,et al. Presence of Host ICAM-1 in Laboratory and Clinical Strains of Human Immunodeficiency Virus Type 1 Increases Virus Infectivity and CD4+-T-Cell Depletion in Human Lymphoid Tissue, a Major Site of Replication In Vivo , 2002, Journal of Virology.
[23] J. Schlom,et al. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). , 2001, Vaccine.
[24] Graça Raposo,et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Lederman,et al. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. , 2001, The Journal of clinical investigation.
[26] L. Meijer,et al. Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors , 2001, Journal of Virology.
[27] B. Clarke,et al. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. , 2001, Gynecologic oncology.
[28] L Leoni,et al. Temporal gene regulation during HIV-1 infection of human CD4+ T cells. , 2001, Genome research.
[29] M. Tremblay,et al. Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process. , 2001, Virology.
[30] S. Brogna,et al. Dribble, the Drosophila KRR1p homologue, is involved in rRNA processing. , 2001, Molecular biology of the cell.
[31] K. Sandhoff,et al. Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. , 2001, The Journal of biological chemistry.
[32] M. Moriuchi,et al. Octamer Transcription Factors Up-regulate the Expression of CCR5, a Coreceptor for HIV-1 Entry* , 2001, The Journal of Biological Chemistry.
[33] Y. Kikuchi,et al. Yeast Krr1p Physically and Functionally Interacts with a Novel Essential Kri1p, and Both Proteins Are Required for 40S Ribosome Biogenesis in the Nucleolus , 2000, Molecular and Cellular Biology.
[34] F. Kashanchi,et al. Loss of G1/S Checkpoint in Human Immunodeficiency Virus Type 1-Infected Cells Is Associated with a Lack of Cyclin-Dependent Kinase Inhibitor p21/Waf1 , 2000, Journal of Virology.
[35] F. Kashanchi,et al. Cell Cycle-Regulated Transcription by the Human Immunodeficiency Virus Type 1 Tat Transactivator , 2000, Journal of Virology.
[36] M. Mizokami,et al. Human IgM Monoclonal Antibody to Ganglioside GM2 and Complement Suppress Virus Propagation in Ex Vivo Cultures of Lymphocytes from HIV‐1 Infected Patients , 1999, Microbiology and immunology.
[37] D. Baltimore,et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. , 1999, Immunity.
[38] C. Thiele,et al. Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. , 1999, Journal of immunology.
[39] A. Chalian,et al. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. , 1999, The Journal of clinical investigation.
[40] H. Koeffler,et al. Functions of Cyclin A1 in the Cell Cycle and Its Interactions with Transcription Factor E2F-1 and the Rb Family of Proteins , 1999, Molecular and Cellular Biology.
[41] R. Irie,et al. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2. , 1999, Journal of immunology.
[42] A. Giordano,et al. HIV-1 Tat Elongates the G1 Phase and Indirectly Promotes HIV-1 Gene Expression in Cells of Glial Origin* , 1998, The Journal of Biological Chemistry.
[43] Y. Ito,et al. Human immunodeficiency virus type-1 envelope glycoprotein gp120 induces expression of fusion regulatory protein (FRP)-1/CD98 on CD4+ T cells: a possible regulatory mechanism of HIV-induced syncytium formation. , 1997 .
[44] D. Latchman,et al. The octamer-binding proteins Oct-1 and Oct-2 repress the HIV long terminal repeat promoter and its transactivation by Tat. , 1997, The Biochemical journal.
[45] H. Haugen,et al. Regulation of an extrathymic T-cell development pathway by oncostatin M , 1996, Nature.
[46] D. Latchman,et al. Functional interaction between the HIV-1 Tat transactivator and the inhibitory domain of the Oct-2 cellular transcription factor , 1996, AIDS.
[47] M. Dierich,et al. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) , 1996, The Journal of experimental medicine.
[48] G. Peters,et al. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. , 1995, Oncogene.
[49] K. Pollok,et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP , 1995, The Journal of experimental medicine.
[50] G. Sutherland,et al. Moslecular and biological characterization of human 4‐1BB and its ligands , 1994, European journal of immunology.
[51] P. Gallay,et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. , 2003, Immunity.
[52] F. Kashanchi,et al. Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. , 2002, The Journal of biological chemistry.
[53] R. Gromadka,et al. The KRR1 gene encodes a protein required for 18S rRNA synthesis and 40S ribosomal subunit assembly in Saccharomyces cerevisiae. , 2000, Acta biochimica Polonica.
[54] Esa Alhoniemi,et al. SOM Toolbox for Matlab 5 , 2000 .
[55] Teuvo Kohonen,et al. Self-Organizing Maps , 2010 .
[56] G. Shanmugam,et al. Retinoblastoma gene inhibits transactivation of HIV-LTR linked gene expression upon co-transfection in He La cells. , 1993, Biochemistry and molecular biology international.